Champions Oncology Q1 Revenue up 9% to $15.2M

Champions Oncology Inc. posted first-quarter revenue of $15.2 million for fiscal 2027, a 9% increase from the $14 million reported in the same period last year. The company achieved a 50% gross margin, up from 43% in the prior-year quarter, while adjusted EBITDA reached $671,000. This marks the fifth consecutive quarter of positive adjusted EBITDA, signaling improved operational leverage despite a GAAP net loss of $426,000.

According to filings cited by GN markets/earnings, the margin improvement was primarily driven by the oncology services segment, where gross margin climbed to 51% from 43%. CFO David Miller attributed this shift to a $500,000 reduction in cost of oncology revenue, which fell to $7.5 million from $8 million despite higher sales. The cost savings resulted from internalizing third-party radio labeling capabilities, allowing the company to capture more value per dollar of revenue.

Data Licensing Revenue Surges

Data licensing emerged as a significant growth driver, generating $893,000 in Q1 fiscal 2027. This single-quarter figure exceeds the total data revenue generated across all of fiscal 2026, reflecting a broader customer base built over the past year. CEO Rob Brainin noted that while the pipeline remains robust, revenue recognition for data contracts is lumpy and dependent on individual closing timelines. Consequently, management advises evaluating this segment on an annual basis rather than quarterly to better assess underlying growth.

The strategic positioning of the data business is tied to the increasing demand for clinically annotated, patient-derived data in AI-driven drug development. Brainin stated that the primary constraint for sponsors adopting machine learning is not model architecture, but the scarcity of high-quality data. Champions aims to leverage its data assets to help sponsors identify patient signatures and design more effective trials, moving beyond single-study predictions toward broader trial design support.

Expense Growth and Cash Position

Sales and marketing expenses increased sharply to $3 million from $1.8 million in the prior-year quarter. Miller explained that this reflects a deliberate investment in expanding the commercial organization to support growth in both services and data. However, the company’s cash balance decreased to $4.4 million, with approximately $500,000 used in operations during the quarter. This reduction in liquidity may limit financial flexibility, particularly as the company continues to invest in commercial expansion.

Corellia Subsidiary Strategy Remains Active

Champions Oncology continues to explore strategic options for Corellia, its wholly owned therapeutic subsidiary. Brainin indicated that external conversations with venture groups and potential pharmaceutical partners are ongoing, with data generation strengthening the company’s case for collaboration. Management declined to provide a specific timeline for outcomes but noted that securing outside funding or a licensing deal would allow the company to redeploy resources currently flowing into Corellia toward other growth initiatives, particularly the data business and bottom-line improvement.